These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 35195819)

  • 21. Comparative efficacy and safety of therapeutics for elderly glioblastoma patients: A Bayesian network analysis.
    Zhao B; Wu J; Xia Y; Li H; Wang Y; Qu T; Xing H; Wang Y; Ma W
    Pharmacol Res; 2022 Aug; 182():106316. PubMed ID: 35724820
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Congress of neurological surgeons systematic review and evidence-based guidelines update on the role of emerging developments in the management of newly diagnosed glioblastoma.
    Farrell C; Shi W; Bodman A; Olson JJ
    J Neurooncol; 2020 Nov; 150(2):269-359. PubMed ID: 33215345
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of long-term adjuvant temozolomide chemotherapy on primary glioblastoma patient survival.
    Huang B; Yu Z; Liang R
    BMC Neurol; 2021 Nov; 21(1):424. PubMed ID: 34724914
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Metronomic Temozolomide in Heavily Pretreated Patients With Recurrent Isocitrate Dehydrogenase Wild-type Glioblastoma: A Large Real-Life Mono-Institutional Study.
    Bosio A; Cerretti G; Padovan M; Caccese M; Denaro L; Chioffi F; Della Puppa A; Aldegheri V; Guarneri V; Zagonel V; Lombardi G
    Clin Oncol (R Coll Radiol); 2023 May; 35(5):e319-e327. PubMed ID: 36858930
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fotemustine as second-line treatment for recurrent or progressive glioblastoma after concomitant and/or adjuvant temozolomide: a phase II trial of Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).
    Brandes AA; Tosoni A; Franceschi E; Blatt V; Santoro A; Faedi M; Amistà P; Gardiman M; Labianca R; Bianchini C; Ermani M; Reni M
    Cancer Chemother Pharmacol; 2009 Sep; 64(4):769-75. PubMed ID: 19169684
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The value of temozolomide in combination with radiotherapy during standard treatment for newly diagnosed glioblastoma.
    Park CK; Lee SH; Kim TM; Choi SH; Park SH; Heo DS; Kim IH; Jung HW
    J Neurooncol; 2013 Apr; 112(2):277-83. PubMed ID: 23377829
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of newly diagnosed glioblastoma in the elderly: a network meta-analysis.
    Hanna C; Lawrie TA; Rogozińska E; Kernohan A; Jefferies S; Bulbeck H; Ali UM; Robinson T; Grant R
    Cochrane Database Syst Rev; 2020 Mar; 3(3):CD013261. PubMed ID: 32202316
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic value of MGMT promoter status in non-resectable glioblastoma after adjuvant therapy.
    Iaccarino C; Orlandi E; Ruggeri F; Nicoli D; Torricelli F; Maggi M; Cerasti D; Pisanello A; Pedrazzi G; Froio E; Crafa P; D'Abbiero N; Michiara M; Ghadirpour R; Servadei F
    Clin Neurol Neurosurg; 2015 May; 132():1-8. PubMed ID: 25723791
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of elderly patients with glioblastoma: a systematic evidence-based analysis.
    Zarnett OJ; Sahgal A; Gosio J; Perry J; Berger MS; Chang S; Das S
    JAMA Neurol; 2015 May; 72(5):589-96. PubMed ID: 25822375
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of protracted temozolomide dosing is limited in MGMT unmethylated GBM xenograft models.
    Cen L; Carlson BL; Pokorny JL; Mladek AC; Grogan PT; Schroeder MA; Decker PA; Anderson SK; Giannini C; Wu W; Ballman KV; Kitange GJ; Sarkaria JN
    Neuro Oncol; 2013 Jun; 15(6):735-46. PubMed ID: 23479134
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Survival benefits of hypofractionated radiotherapy combined with temozolomide or temozolomide plus bevacizumab in elderly patients with glioblastoma aged ≥ 75 years.
    Ohno M; Miyakita Y; Takahashi M; Igaki H; Matsushita Y; Ichimura K; Narita Y
    Radiat Oncol; 2019 Nov; 14(1):200. PubMed ID: 31718669
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Differences in clinical outcomes based on molecular markers in glioblastoma patients treated with concurrent tumor-treating fields and chemoradiation: exploratory analysis of the SPARE trial.
    Cappelli L; Khan MM; Kayne A; Poiset S; Miller R; Ali A; Niazi M; Shi W; Alnahhas I
    Chin Clin Oncol; 2023 Jun; 12(3):23. PubMed ID: 37417289
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Randomized study of postoperative radiotherapy and simultaneous temozolomide without adjuvant chemotherapy for glioblastoma.
    Kocher M; Frommolt P; Borberg SK; Rühl U; Steingräber M; Niewald M; Staar S; Stuschke M; Becker G; Fischedick AR; Herfarth K; Grauthoff H; Müller RP
    Strahlenther Onkol; 2008 Nov; 184(11):572-9. PubMed ID: 19016015
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Second-line chemotherapy with fotemustine in temozolomide-pretreated patients with relapsing glioblastoma: a single institution experience.
    Scoccianti S; Detti B; Sardaro A; Iannalfi A; Meattini I; Leonulli BG; Borghesi S; Martinelli F; Bordi L; Ammannati F; Biti G
    Anticancer Drugs; 2008 Jul; 19(6):613-20. PubMed ID: 18525321
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A meta-analysis of temozolomide versus radiotherapy in elderly glioblastoma patients.
    Yin AA; Cai S; Dong Y; Zhang LH; Liu BL; Cheng JX; Zhang X
    J Neurooncol; 2014 Jan; 116(2):315-24. PubMed ID: 24178440
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial.
    Mirimanoff RO; Gorlia T; Mason W; Van den Bent MJ; Kortmann RD; Fisher B; Reni M; Brandes AA; Curschmann J; Villa S; Cairncross G; Allgeier A; Lacombe D; Stupp R
    J Clin Oncol; 2006 Jun; 24(16):2563-9. PubMed ID: 16735709
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Radiosensitizing effects of temozolomide observed in vivo only in a subset of O6-methylguanine-DNA methyltransferase methylated glioblastoma multiforme xenografts.
    Carlson BL; Grogan PT; Mladek AC; Schroeder MA; Kitange GJ; Decker PA; Giannini C; Wu W; Ballman KA; James CD; Sarkaria JN
    Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):212-9. PubMed ID: 19695438
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Congress of Neurological Surgeons systematic review and evidence-based guidelines update on the role of radiation therapy in the management of progressive and recurrent glioblastoma in adults.
    Ziu M; Goyal S; Olson JJ
    J Neurooncol; 2022 Jun; 158(2):255-264. PubMed ID: 34748120
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The added value of concurrently administered temozolomide versus adjuvant temozolomide alone in newly diagnosed glioblastoma.
    Sher DJ; Henson JW; Avutu B; Hochberg FH; Batchelor TT; Martuza RL; Barker FG; Loeffler JS; Chakravarti A
    J Neurooncol; 2008 May; 88(1):43-50. PubMed ID: 18231723
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bone marrow response as a potential biomarker of outcomes in glioblastoma patients.
    Vaios EJ; Nahed BV; Muzikansky A; Fathi AT; Dietrich J
    J Neurosurg; 2017 Jul; 127(1):132-138. PubMed ID: 27739940
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.